Osimertinib-Induced Cardiomyopathy

Osimertinib-Induced Cardiomyopathy

Osimertinib is the preferred treatment in patients with metastatic non–small cell lung cancer with epidermal growth factor receptor mutations. We report a case series of acute cardiomyopathy with heart failure exacerbation during osimertinib treatment. We suggest that cardiotoxicity from osimertinib...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JACC. Case reports 2020-04, Vol.2 (4), p.641-645
Hauptverfasser: Patel, Shruti R., Brown, Sherry-Ann N., Kubusek, Jilan E., Mansfield, Aaron S., Duma, Narjust
Format: Artikel
Sprache:eng
Schlagworte:
cardio-oncology
cardiotoxicity
Case Report
heart failure
osimertinib
reduced ejection fraction
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Osimertinib is the preferred treatment in patients with metastatic non–small cell lung cancer with epidermal growth factor receptor mutations. We report a case series of acute cardiomyopathy with heart failure exacerbation during osimertinib treatment. We suggest that cardiotoxicity from osimertinib is reversible and occurs at a dose of 80 mg/day. (Level of Difficulty: Intermediate.) [Display omitted] Osimertinib is the preferred treatment in patients with metastatic non–small cell lung cancer with epidermal growth factor receptor mutations…
ISSN:2666-0849
2666-0849
DOI:10.1016/j.jaccas.2019.12.038